A mechanism for hypoxia-induced inflammatory cell death in cancer – Nature
Bertout, J. A., Patel, S. A. & Simon, M. C. The impact of O2 availability on human cancer. Nat. Rev. Cancer 8, 967–975 (2008).
Google Scholar
Singleton, D. C., Macann, A. & Wilson, W. R. Therapeutic targeting of the hypoxic tumour microenvironment. Nat. Rev. Clin. Oncol. 18, 751–772 (2021).
Google Scholar
Banh, R. S. et al. PTP1B controls non-mitochondrial oxygen consumption by regulating RNF213 to promote tumour survival during hypoxia. Nat. Cell Biol. 18, 803–813 (2016).
Google Scholar
Asselman, C., Hemelsoet, D., Eggermont, D., Dermaut, B. & Impens, F. Moyamoya disease emerging as an immune-related angiopathy. Trends Mol. Med. 28, 939–950 (2022).
Google Scholar
Schofield, C. J. & Ratcliffe, P. J. Oxygen sensing by HIF hydroxylases. Nat. Rev. Mol. Cell Biol. 5, 343–354 (2004).
Google Scholar
Wouters, B. G. & Koritzinsky, M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat. Rev. Cancer 8, 851–864 (2008).
Google Scholar
Cummins, E. P. et al. Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc. Natl Acad. Sci. USA 103, 18154–18159 (2006).
Google Scholar
Rius, J. et al. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 453, 807–811 (2008).
Google Scholar
Eltzschig, H. K. & Carmeliet, P. Hypoxia and inflammation. N. Engl. J. Med. 364, 656–665 (2011).
Google Scholar
Kroemer, G., Galluzzi, L., Kepp, O. & Zitvogel, L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31, 51–72 (2013).
Google Scholar
Nizet, V. & Johnson, R. S. Interdependence of hypoxic and innate immune responses. Nat. Rev. Immunol. 9, 609–617 (2009).
Google Scholar
Pakos-Zebrucka, K. et al. The integrated stress response. EMBO Rep. 17, 1374–1395 (2016).
Google Scholar
Delibegovic, M., Dall’Angelo, S. & Dekeryte, R. Protein tyrosine phosphatase 1B in metabolic diseases and drug development. Nat. Rev. Endocrinol. 20, 366–378 (2024).
Google Scholar
The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61–70 (2012).
Google Scholar
Ahel, J. et al. Moyamoya disease factor RNF213 is a giant E3 ligase with a dynein-like core and a distinct ubiquitin-transfer mechanism. eLife 9, e56185 (2020).
Google Scholar
Otten, E. G. et al. Ubiquitylation of lipopolysaccharide by RNF213 during bacterial infection. Nature 594, 111–116 (2021).
Google Scholar
Morito, D. et al. Moyamoya disease-associated protein mysterin/RNF213 is a novel AAA+ ATPase, which dynamically changes its oligomeric state. Sci. Rep. 4, 4442 (2014).
Google Scholar
Piccolis, M. et al. Probing the global cellular responses to lipotoxicity caused by saturated fatty acids. Mol. Cell 74, 32–44 (2019).
Google Scholar
Sugihara, M. et al. The AAA+ ATPase/ubiquitin ligase mysterin stabilizes cytoplasmic lipid droplets. J. Cell Biol. 218, 949–960 (2019).
Google Scholar
Thery, F. et al. Ring finger protein 213 assembles into a sensor for ISGylated proteins with antimicrobial activity. Nat. Commun. 12, 5772 (2021).
Google Scholar
Takeda, M. et al. Moyamoya disease patient mutations in the RING domain of RNF213 reduce its ubiquitin ligase activity and enhance NFkappaB activation and apoptosis in an AAA+ domain-dependent manner. Biochem. Biophys. Res. Commun. 525, 668–674 (2020).
Google Scholar
LaMontagne, K. R. Jr, Hannon, G. & Tonks, N. K. Protein tyrosine phosphatase PTP1B suppresses p210 bcr-abl-induced transformation of rat-1 fibroblasts and promotes differentiation of K562 cells. Proc. Natl Acad. Sci. USA 95, 14094–14099 (1998).
Google Scholar
Kotani, Y. et al. Alternative exon skipping biases substrate preference of the deubiquitylase USP15 for mysterin/RNF213, the moyamoya disease susceptibility factor. Sci. Rep. 7, 44293 (2017).
Google Scholar
Kovalenko, A. et al. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 424, 801–805 (2003).
Google Scholar
Schlicher, L., Brauns-Schubert, P., Schubert, F. & Maurer, U. SPATA2: more than a missing link. Cell Death Differ. 24, 1142–1147 (2017).
Google Scholar
Louvrier, C. et al. RNF213-associated urticarial lesions with hypercytokinemia. J. Allergy Clin. Immunol. 150, 1545–1555 (2022).
Google Scholar
Bhardwaj, A., Banh, R. S., Zhang, W., Sidhu, S. S. & Neel, B. G. MMD-associated RNF213 SNPs encode dominant-negative alleles that globally impair ubiquitylation. Life Sci. Alliance 5, e202000807 (2022).
Google Scholar
Cecchi, A. C. et al. RNF213 rare variants in an ethnically diverse population with Moyamoya disease. Stroke 45, 3200–3207 (2014).
Google Scholar
Kamada, F. et al. A genome-wide association study identifies RNF213 as the first Moyamoya disease gene. J. Hum. Genet. 56, 34–40 (2011).
Google Scholar
Liu, W. et al. Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS ONE 6, e22542 (2011).
Google Scholar
Taniguchi, K. & Karin, M. NF-kappaB, inflammation, immunity and cancer: coming of age. Nat. Rev. Immunol. 18, 309–324 (2018).
Google Scholar
He, Y., Hara, H. & Nunez, G. Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem. Sci 41, 1012–1021 (2016).
Google Scholar
Karki, R. & Kanneganti, T. D. Diverging inflammasome signals in tumorigenesis and potential targeting. Nat. Rev. Cancer 19, 197–214 (2019).
Google Scholar
Diaz-Rodriguez, E. et al. TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells. Cancer Lett. 453, 34–44 (2019).
Google Scholar
Endo, M., Mori, M., Akira, S. & Gotoh, T. C/EBP homologous protein (CHOP) is crucial for the induction of caspase-11 and the pathogenesis of lipopolysaccharide-induced inflammation. J. Immunol. 176, 6245–6253 (2006).
Google Scholar
An, J. et al. Inactivation of the CYLD deubiquitinase by HPV E6 mediates hypoxia-induced NF-kappaB activation. Cancer Cell 14, 394–407 (2008).
Google Scholar
Wiede, F. et al. PTP1B is an intracellular checkpoint that limits T-cell and CAR T-cell antitumor immunity. Cancer Discov. 12, 752–773 (2022).
Google Scholar
Baumgartner, C. K. et al. The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity. Nature 622, 850–862 (2023).
Google Scholar
Gibson, D. G. et al. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat. Methods 6, 343–345 (2009).
Google Scholar
Fedele, C. et al. SHP2 inhibition prevents adaptive resistance to MEK inhibitors in multiple cancer models. Cancer Discov. 8, 1237–1249 (2018).
Google Scholar
Marcotte, R. et al. Functional genomic landscape of human breast cancer drivers, vulnerabilities, and resistance. Cell 164, 293–309 (2016).
Google Scholar
Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281–2308 (2013).
Google Scholar
Zhang, S. et al. Genetically defined, syngeneic organoid platform for developing combination therapies for ovarian cancer. Cancer Discov. 11, 362–383 (2021).
Google Scholar
Martinez, A. M., Kim, A. & Yang, W. S. Detection of ferroptosis by BODIPY 581/591 C11. Methods Mol. Biol. 2108, 125–130 (2020).
Google Scholar
Branon, T. C. et al. Efficient proximity labeling in living cells and organisms with TurboID. Nat. Biotechnol. 36, 880–887 (2018).
Google Scholar
Teo, G. et al. SAINTexpress: improvements and additional features in Significance Analysis of INTeractome software. J. Proteomics 100, 37–43 (2014).
Google Scholar
